-
23 April 2026 15:43:15
- Source: Sharecast
Hikma Pharmaceuticals PLC
Results of 2026 Annual General Meeting
LONDON, 23 April 2026 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (the 'Company' or 'Hikma') announces that its Annual General Meeting ('AGM') was held at Sofitel London St James, 6 Waterloo Place, London SW1Y 4AN earlier today (23 April 2026) and commenced at 11.00 am. All the proposed resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 16 (inclusive) were passed as ordinary resolutions and Resolutions 17 to 20 (inclusive) were passed as special resolutions. Resolutions 21 to 22 (inclusive) were passed as ordinary resolutions on which only Independent Shareholders (that is, excluding members of the Concert Party, in accordance with the City Code on Takeovers and Mergers) were entitled to vote.
Copies of the resolutions dealing with special business passed at the AGM have been submitted to the FCA's Electronic Submission System and will be available from the National Storage Mechanism. Capitalised terms used but not otherwise defined in this announcement shall have the meanings given to them in the Notice of Meeting dated 18 March 2026.
The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the Notice of Meeting dated 18 March 2026) is set out below. The number of Ordinary Shares in issue at the close of business on 21 April 2026 was 230,345,591. At that time there were 12,833,233 Ordinary Shares held in treasury, which are not counted in the voting capital of the Company which, therefore, was 217,512,358.
|
Resolution |
Votes For |
% of Eligible Votes |
Votes Against |
% of Eligible Votes |
Total Votes Cast |
Total votes cast as a % of ISC1 |
Withheld2 |
|
1. To receive the 2025 report and accounts |
163,275,312 |
99.99% |
17,475 |
0.01% |
163,292,787 |
75.07% |
1,019,017 |
|
2. To approve a final dividend of 48 cents per share |
164,299,386 |
99.99% |
6,064 |
0.01% |
164,305,450 |
75.54% |
6,354 |
|
3. To re-appoint PricewaterhouseCoopers LLP as Auditor |
163,553,679 |
99.57% |
705,615 |
0.43% |
164,259,294 |
75.52% |
52,510 |
|
4. To authorise the Audit Committee to determine the remuneration of the Auditor |
164,274,950 |
99.99% |
23,884 |
0.01% |
164,298,834 |
75.54% |
12,970 |
|
5. To elect Khalid Nabilsi as a Director |
162,775,703 |
99.08% |
1,514,619 |
0.92% |
164,290,322 |
75.53% |
21,482 |
|
6. To re-elect Victoria Hull as a Director |
161,115,526 |
98.09% |
3,135,584 |
1.91% |
164,251,110 |
75.51% |
60,694 |
|
7. To re-elect Said Darwazah as a Director |
162,778,631 |
99.08% |
1,511,493 |
0.92% |
164,290,124 |
75.53% |
21,680 |
|
8. To re-elect Mazen Darwazah as a Director |
160,180,915 |
97.50% |
4,107,459 |
2.50% |
164,288,374 |
75.53% |
23,430 |
|
9. To re-elect Douglas Hurt as a Director |
163,661,379 |
99.64% |
591,090 |
0.36% |
164,252,469 |
75.51% |
59,335 |
|
10. To re-elect Ali Al-Husry as a Director |
162,593,736 |
98.99% |
1,657,276 |
1.01% |
164,251,012 |
75.51% |
60,792 |
|
11. To re-elect Cynthia Flowers as a Director |
164,036,930 |
99.87% |
214,050 |
0.13% |
164,250,980 |
75.51% |
60,824 |
|
12. To re-elect Laura Balan as a Director |
164,087,521 |
99.90% |
167,257 |
0.10% |
164,254,778 |
75.52% |
57,026 |
|
13. To re-elect Dr Deneen Vojta as a Director |
163,468,063 |
99.88% |
201,369 |
0.12% |
163,669,432 |
75.25% |
642,372 |
|
14. To receive and approve the annual report on remuneration |
159,288,908 |
96.98% |
4,961,703 |
3.02% |
164,250,611 |
75.51% |
61,193 |
|
15. To approve the Directors' Remuneration Policy |
162,548,305 |
98.96% |
1,700,931 |
1.04% |
164,249,236 |
75.51% |
62,568 |
|
16. To authorise the Directors to allot shares and grant rights to subscribe for shares |
161,666,855 |
98.40% |
2,622,154 |
1.60% |
164,289,009 |
75.53% |
22,795 |
|
17. To authorise the disapplication of pre-emption rights (General) |
159,554,398 |
97.12% |
4,735,766 |
2.88% |
164,290,164 |
75.53% |
21,640 |
|
18. To authorise the disapplication of pre-emption rights (Acquisition or Capital Investment) |
149,676,154 |
91.10% |
14,614,113 |
8.90% |
164,290,267 |
75.53% |
21,537 |
|
19. To authorise the Company to purchase its own Ordinary Shares |
164,030,277 |
99.96% |
64,165 |
0.04% |
164,094,442 |
75.44% |
217,362 |
|
20. To authorise the Company to hold general meetings on not less than 14 clear days' notice |
161,251,197 |
98.14% |
3,053,144 |
1.86% |
164,304,341 |
75.54% |
7,463 |
|
21. To approve the Rule 9 Waiver (Buyback Waiver) 3 |
92,574,383 |
91.26% |
8,869,249 |
8.74% |
101,443,632 |
46.64% |
2,868,172 |
|
22. To approve the Rule 9 Waiver (2027 Awards Waiver)3 |
97,017,031 |
95.65% |
4,416,329 |
4.35% |
101,433,360 |
46.63% |
2,878,444 |
1 Issued Ordinary Share capital of the Company (excluding treasury shares) at the close of business on 21 April 2026.
2 A "withheld" vote is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
3 In order to comply with the City Code on Takeovers and Mergers, only the votes cast by independent shareholders were counted for the purposes of Resolutions 21 to 22.
Declaration of final dividend
The dividend of 48 cents per share will be paid on 30 April 2026 to shareholders on the register at the close of business on 20 March 2026. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.36 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa $1 to 0.708JD.
Approval of Rule 9 Waiver
The number of Ordinary Shares in which the Concert Party was collectively interested in at the close of business on 21 April 2026 was 65,146,443, representing approximately 29.95% of the Ordinary Shares carrying voting rights in the capital of the Company.
The combined effect of the Buyback Waiver, the 2027 Awards Waiver and the Company's pre-existing Rule 9 waivers as approved by shareholders at the 2024 AGM and the 2025 AGM would allow the Concert Party's interest in Ordinary Shares as a proportion of the Company's total share capital to increase, but only to the extent that the resulting interest of the Concert Party would not exceed 33.99% of the issued and voting share capital of the Company.
- ENDS -
Enquiries:
|
Hikma Pharmaceuticals PLC |
|
|
Helen Middlemist Group Company Secretary |
+44 20 7399 2670 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.